Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Ionis Pharmaceuticals, Inc. (IONS)

35.74   0.85 (2.44%) 03-31 16:00
Open: 35.08 Pre. Close: 34.89
High: 35.78 Low: 35.08
Volume: 873,661 Market Cap: 5,286(M)

Technical analysis

as of: 2023-03-31 4:19:43 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 43     One year: 50.23
Support: Support1: 34.26    Support2: 32.68
Resistance: Resistance1: 36.81    Resistance2: 43
Pivot: 34.66
Moving Average: MA(5): 34.82     MA(20): 34.8
MA(100): 38.52     MA(250): 39.87
MACD: MACD(12,26): -0.6     Signal(9): -0.8
Stochastic oscillator: %K(14,3): 69     %D(3): 57.4
RSI: RSI(14): 51.5
52-week: High: 48.81  Low: 31.45
Average Vol(K): 3-Month: 944 (K)  10-Days: 1,007 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ IONS ] has closed below upper band by 15.7%. Bollinger Bands are 24.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 35.81 - 36 36 - 36.16
Low: 33.97 - 34.18 34.18 - 34.36
Close: 34.54 - 34.9 34.9 - 35.21

Company Description

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

Headline News

Fri, 31 Mar 2023
Ionis Pharmaceuticals, Inc.: A Revolutionary Drug Discovery ... - Best Stocks

Thu, 30 Mar 2023
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Consensus ... - MarketBeat

Wed, 29 Mar 2023
New data presented at AD/PD™2023 show IONIS-MAPT Rx ... - PR Newswire

Tue, 28 Mar 2023
2023-03-28 | NDAQ:IONS | Press Release | Ionis Pharmaceuticals Inc. - Stockhouse

Tue, 28 Mar 2023
Ionis to present at upcoming investor conferences - PR Newswire

Mon, 27 Mar 2023
Ionis Pharmaceuticals (IONS) Reports Positive 66-week Phase 3 ... -

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 143 (M)
Shares Float 142 (M)
% Held by Insiders 0.5 (%)
% Held by Institutions 93.8 (%)
Shares Short 8,170 (K)
Shares Short P.Month 8,180 (K)

Stock Financials

EPS -1.99
EPS Est Next Qtl -0.1
EPS Est This Year -0.18
EPS Est Next Year 0.05
Book Value (p.s.) 4.03
Profit Margin (%) -46
Operating Margin (%) -69.5
Return on Assets (ttm) -10
Return on Equity (ttm) -40.2
Qtrly Rev. Growth -65.5
Gross Profit (p.s.) -1.81
Sales Per Share 4.1
EBITDA (p.s.) -2.74
Qtrly Earnings Growth 0
Operating Cash Flow -274 (M)
Levered Free Cash Flow -75 (M)

Stock Valuations

PE Ratio -18.06
PEG Ratio 0.1
Price to Book value 8.86
Price to Sales 8.69
Price to Cash Flow -18.63

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.